company background image
CJH logo

CanSino Biologics BST:CJH Stock Report

Last Price

€4.00

Market Cap

€1.4b

7D

0%

1Y

59.4%

Updated

26 Dec, 2024

Data

Company Financials +

CJH Stock Overview

Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details

CJH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CanSino Biologics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CanSino Biologics
Historical stock prices
Current Share PriceHK$4.00
52 Week HighHK$4.00
52 Week LowHK$1.85
Beta0.46
1 Month Change27.39%
3 Month Change65.29%
1 Year Change59.36%
3 Year Change-80.37%
5 Year Change-36.51%
Change since IPO-15.81%

Recent News & Updates

Recent updates

Shareholder Returns

CJHDE BiotechsDE Market
7D0%1.2%-0.3%
1Y59.4%-14.3%7.0%

Return vs Industry: CJH exceeded the German Biotechs industry which returned -13% over the past year.

Return vs Market: CJH exceeded the German Market which returned 6.8% over the past year.

Price Volatility

Is CJH's price volatile compared to industry and market?
CJH volatility
CJH Average Weekly Movementn/a
Biotechs Industry Average Movement7.0%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: CJH's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine CJH's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,149Xuefeng Yuwww.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

CanSino Biologics Inc. Fundamentals Summary

How do CanSino Biologics's earnings and revenue compare to its market cap?
CJH fundamental statistics
Market cap€1.39b
Earnings (TTM)-€94.80m
Revenue (TTM)€98.54m

9.2x

P/S Ratio

-9.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CJH income statement (TTM)
RevenueCN¥748.53m
Cost of RevenueCN¥774.40m
Gross Profit-CN¥25.87m
Other ExpensesCN¥694.25m
Earnings-CN¥720.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin-3.46%
Net Profit Margin-96.20%
Debt/Equity Ratio41.3%

How did CJH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 22:18
End of Day Share Price 2024/12/12 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CanSino Biologics Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Lijian ZhaoChina International Capital Corporation Limited
Hangci ZhengChina International Capital Corporation Limited